Brief: Acorda Therapeutics And Biopas Laboratories Agree To Commercialize Inbrija In Latin America
11/05/2022 21:37
May 11 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS AND BIOPAS LABORATORIES ANNOUNCE
AGREEMENT
TO COMMERCIALIZE INBRIJA® IN LATIN AMERICA
* ACORDA THERAPEUTICS - IN DEAL, WILL RECEIVE A
DOUBLE-DIGIT,
TIERED PERCENTAGE OF SELLING PRICE OF INBRIJA IN LATIN AMERICA
FOR SUPPLY OF PRODUCT
* ACORDA THERAPEUTICS INC - ACORDA WILL ALSO RECEIVE
SALES-BASED
MILESTONES
* ACORDA THERAPEUTICS - BIOPAS WILL HAVE EXCLUSIVE
DISTRIBUTION
RIGHTS TO INBRIJA IN NINE COUNTRIES WITHIN LATIN AMERICA,
INCLUDING BRAZIL AND MEXICO
Source text for Eikon: ID:nBw56GDrGa
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease